Drug intelligence / Profile preview

KJ017

Development stage: Unknown
Lead developer: Shanghai Bao Pharmaceuticals
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

**KJ017** is a highly glycosylated recombinant human hyaluronidase (rHuPH20) enzyme developed by Bao Pharma for subcutaneous drug delivery. It enzymatically degrades hyaluronic acid (HA) in the subcutaneous tissue, temporarily increasing tissue permeability to enable rapid, high-volume subcutaneous administration of co-formulated drugs or biologics, facilitating a shift from intravenous to self-administrable settings. This enhances patient convenience, safety, and supports lifecycle management of therapies; it is also indicated as an adjuvant for dermal rehydration due to various causes. Currently in NDA/BLA stage in China.[1][3][5][7]

Brand names: Hysorptase

Beyond the preview

Go deeper on KJ017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KJ017.

Explore the full profile